Advances in Asthma Therapy with a Focus on Monoclonal Antibodies
Asthma can be well controlled in most patients with a basic therapy consisting of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) or anticholinergics (LAMA). However, in some cases, severe asthma develops despite adequate therapy. Here, modern biologics, particularly monoclonal an...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-07-01
|
| Series: | healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses |
| Online Access: | https://doi.org/10.36000/hbT.2024.13.003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849316971712086016 |
|---|---|
| author | Marcus Hesse |
| author_facet | Marcus Hesse |
| author_sort | Marcus Hesse |
| collection | DOAJ |
| description | Asthma can be well controlled in most patients with a basic therapy consisting of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) or anticholinergics (LAMA). However, in some cases, severe asthma develops despite adequate therapy. Here, modern biologics, particularly monoclonal antibodies, can be used, targeting various pro-inflammatory factors. Targets would be IgE, IL-5, IL-4/IL-13 und thymus-stoma-lymphopoietin (TSLP).
**Zusammenfassung**
Durch eine Basistherapie mit inhalativen Kortikosteroiden (ICS) und langwirksamen Beta-Agonisten (LABA) bzw. Anticholinergika (LAMA) kann Asthma bei den meisten Patienten gut kontrolliert werden. In einigen Fällen entwickelt sich jedoch trotz adäquater Therapie ein schweres Asthma. Hier können moderne Biologika, insbesondere monoklonale Antikörper, zum Einsatz kommen, die sich gegen verschiedene entzündungsfördernde Faktoren richten. Targets sind hier IgE, IL-5, IL-4/IL-13 und thymus-stroma-lymphopoietin (TSLP).
PEER REVIEWED ARTICLE
Peer Reviewers:
Three anonymous reviewers
Received: May 20, 2024; accepted after peer review: June 20, 2024. |
| format | Article |
| id | doaj-art-294907b0c2ee40af874c1ead8c0dc88e |
| institution | Kabale University |
| issn | 2673-8406 2673-8414 |
| language | deu |
| publishDate | 2024-07-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses |
| spelling | doaj-art-294907b0c2ee40af874c1ead8c0dc88e2025-08-20T03:51:24ZdeuTHE HEALTHBOOK COMPANY LTD.healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses2673-84062673-84142024-07-0113210.36000/hbT.2024.13.003Advances in Asthma Therapy with a Focus on Monoclonal AntibodiesMarcus HesseAsthma can be well controlled in most patients with a basic therapy consisting of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) or anticholinergics (LAMA). However, in some cases, severe asthma develops despite adequate therapy. Here, modern biologics, particularly monoclonal antibodies, can be used, targeting various pro-inflammatory factors. Targets would be IgE, IL-5, IL-4/IL-13 und thymus-stoma-lymphopoietin (TSLP). **Zusammenfassung** Durch eine Basistherapie mit inhalativen Kortikosteroiden (ICS) und langwirksamen Beta-Agonisten (LABA) bzw. Anticholinergika (LAMA) kann Asthma bei den meisten Patienten gut kontrolliert werden. In einigen Fällen entwickelt sich jedoch trotz adäquater Therapie ein schweres Asthma. Hier können moderne Biologika, insbesondere monoklonale Antikörper, zum Einsatz kommen, die sich gegen verschiedene entzündungsfördernde Faktoren richten. Targets sind hier IgE, IL-5, IL-4/IL-13 und thymus-stroma-lymphopoietin (TSLP). PEER REVIEWED ARTICLE Peer Reviewers: Three anonymous reviewers Received: May 20, 2024; accepted after peer review: June 20, 2024.https://doi.org/10.36000/hbT.2024.13.003 |
| spellingShingle | Marcus Hesse Advances in Asthma Therapy with a Focus on Monoclonal Antibodies healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses |
| title | Advances in Asthma Therapy with a Focus on Monoclonal Antibodies |
| title_full | Advances in Asthma Therapy with a Focus on Monoclonal Antibodies |
| title_fullStr | Advances in Asthma Therapy with a Focus on Monoclonal Antibodies |
| title_full_unstemmed | Advances in Asthma Therapy with a Focus on Monoclonal Antibodies |
| title_short | Advances in Asthma Therapy with a Focus on Monoclonal Antibodies |
| title_sort | advances in asthma therapy with a focus on monoclonal antibodies |
| url | https://doi.org/10.36000/hbT.2024.13.003 |
| work_keys_str_mv | AT marcushesse advancesinasthmatherapywithafocusonmonoclonalantibodies |